Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medicaid topic
No spam. Unsubscribe anytime.
Committee approves higher Medicaid diagnostic lab cap for chronic‑pain patients
Summary
Senate Bill 348 would raise the annual Medicaid diagnostic laboratory cap for beneficiaries with chronic pain from $500 to $1,800; proponents said expanding testing could avoid costly emergency visits tied to substance‑use disorders, while DHS estimated a conservative state‑share fiscal impact of roughly $100,000 to $600,000.
Senate Bill 348, which raises the annual cap for Medicaid diagnostic laboratory services for beneficiaries being treated for chronic pain from $500 to $1,800, passed the Public Health, Welfare and Labor Committee after testimony from providers and fiscal questions from the Department of Human Services.
Kristen Neck, chief operating officer for AIT Health (affiliated with Pain Treatment Centers of America), said expanding the cap would allow more comprehensive monitoring of chronic‑pain patients and help prevent emergency room visits and inpatient stays tied to substance‑use disorder. She noted the average emergency visit for substance use disorder is roughly $520 and cited $15,000 as an average annual medical cost attributed to substance‑use disorder per affected enrollee.
Janet Mann of the Arkansas Department of Human Services confirmed the proposal has a fiscal impact. DHS provided a conservative state‑share estimate between about $98,000 and $591,000, reflecting the state portion of expanded federal matching. DHS said the benefit is adult‑only and the current $500 cap was created when lab and radiology caps were split.
Kitty Cone, chief legal officer for Pain Treatment Centers of America, said the increase would save thousands of dollars compared with ER and inpatient costs because better monitoring reduces acute episodes. After discussion of fiscal impacts, proponents moved to pass and the committee approved SB348 by voice vote.
